Objectives. Elevated total serum free fatty acids (FFAs) concentrations have been suggested, controversially, to enhance insulin resistance and decrease percent remaining β-cell function. However, concentrations of individual serum FFAs have never been published in terms of their relationship (correlation) to homeostatic model assessment-insulin resistance (HOMA-IR) and percent remaining β-cell function (HOMA-%β) in the type 2 diabetics (T2Ds). Alpha-linolenic acid consumption has a negative correlation with the insulin resistance, which in turn is negatively correlated with the remaining β-cell function. Th e primary objective was to test the hypothesis that there would be diff erent relationship (correlation) between the blood serum individual free FFA mol % levels and HOMA-IR and/or HOMA-%β in T2D. Th e secondary objective was to test the hypothesis that fl axseed oil, previously being shown to be ineff ective in the glycemic control in T2Ds, may alter these correlations in a statistically signifi cant manner as well as HOMA-IR and/ or HOMA-%β.
Insulin resistance and β-cell function, both key components of the management of the type 2 diabetes (T2D), may be assessed by homeostatic model assessment-insulin resistance (HOMA-IR) and homeostatic model assessment-percentage beta cell function (HOMA-%β) (Wallace et al. 2004) .
Elevated concentrations of serum total free fatty acids (FFAs) have been suggested, albeit controversially, to enhance insulin resistance and decrease the β-cell function ( Reaven and Chen 1988; Eriksson et al. 1991; Butler et al. 2001; Blaak 2003; Hawkins et al. 2003; Moore et al. 2004; Robertson et al. 2004; Poitout et al. 2006; Delarue and Magnan 2007; Ye 2007; Poitout and Robertson 2008; Poitout et al. 2010; Boden 2011; Karpe et al. 2011; Morita et al. 2012; Salgin et al. 2012) .
However, mol % levels of the blood serum of the individual FFAs have never been studied for their relationships (correlations) to HOMA-IR or HOMA-%β either under basal conditions or aft er a treatment in the type 2 diabetics (T2Ds). Th e controversial impact of the serum, total individual FFA pool may be a refl ection of the diff erential fatty acid (FA) compositions of the pool in diff erent studies.
As diff erent FAs have diff erent lengths, positional (omega) and geometric (cis, trans) isomers, and hence structure, it is reasonable to suggest that they may diff erentially infl uence the insulin resistance and/or β-cell function. Furthermore, as dietary FA consumption changes, one may fi nd alterations in the relationship of the individual FFAs to each of insulin resistance and pancreatic β-cell function (Newens et al. 2011 ). More specifi cally, alpha-linolenic acid consumption (ALA, 18:3 n-3) has been proposed to reduce insulin resistance in human T2D (Wang et al. 2013) albeit prior to the current study. Generally, the relationship, if any exists, between ALA and pancreatic beta cell function in T2Ds is not clear. However, Armoni et al. (2005) have found elevated concentrations of serum free palmitic acid (PA, 16:0) , stearic acid (SA 18:0), oleic acid (OA, 18:1 n-9) linoleic acid (LA, 18:2 n-6), ALA, and arachidonic acid (AA, relative to healthy controls, while the mol % levels were similar though perhaps inferred to be connected to higher HOMA-IR and lower HOMA-%β. However, the data of other studies have demonstrated diff ering relationships/correlations between the varying mol % levels of serum/plasma individual FFAs and HOMA-IR and/or HOMA-%β (Yi et al. 2007; Liu et al. 2010; Grapov et al. 2012) .
Th ere is an interest in omega 3 FAs to control the blood glucose levels. However, several studies in the 1980s showed a deterioration of glycemic control in patients with T2D consuming high doses of fi sh oil containing eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3) or purifi ed EPA or DHA (Glauber et al. 1998; Woodman et al. 2002; Nettleton and Katz 2005) . However, lower doses of fi sh oil or purifi ed EPA or DHA resulted in no change in the glycemic control (Rivellese et al. 1996; Nakamura et al. 1998; Montori et al. 2000; Nettleton and Katz 2005) . Low doses of fl axseed oil containing ALA did not improve glycemic control in T2Ds. McManus et al. (1996) and Goh et al. (1997) giving 35 mg ALA/kg body weight/day in the form of fl axseed oil for three months, failed to note any change in the fasting blood plasma glucose. Taylor et al. (2010) and Barre et al. (2005a,b; ) also failed to show an impact of fl axseed oil on glucose management in T2Ds, even with much higher doses of fl axseed oil used (81.5 and 60 mg ALA/kg body weight /day, respectively). As ALA is slowly desaturated and elongated to EPA and DHA, it was reasoned that higher doses of ALA should be examined, given that high doses of fl axseed oil dramatically reduce platelet reactivity (Barre et al. 2005a,b) . Th is suggests a signifi cant accumulation of bioactive EPA and DHA, thus rationalizing the current study on high dose ALA. Such information is important to researchers, physicians, and T2D patients dealing with the impact of fl axseed oil on the glucose management by high dose fl axseed oil in T2Ds.
Th e primary objective of this work was to test the hypothesis that there would be diff erent relationships (correlations) between the blood serum individual FFA mol % levels and each of HOMA-IR and/or HOMA-%β in human T2D. Th e secondary objective was to test the hypothesis that fl axseed oil (rich in ALA) supplementation could alter these correlations and consequently HOMA-IR and/or HOMA-%β in comparison with the placebo saffl ower oil (poor in ALA). Th is is the fi rst study examining the potential relationships between serum individual FFA mol % levels and each of HOMA-IR and HOMA-%β in human T2D. Th is study builds on the already published data, including data in Tables 1 and 2, and  parts of Tables 3 and Table 8 (Barre et al. 2008 ).
Materials and Methods
Subjects. Th e inclusion criteria were: 18 years of age or older, T2D and not involvement in the physical training program, not taking insulin or any omega 3 supplement including fi sh oil, not pregnant or planning becoming to be pregnant and not to have contraindication to fl axseed oil or saffl ower oil. Th e exclusion criteria were: those not meeting the inclusion criteria and those with hepatic or kidney disease. Patients were recruited via a Sydney, Nova Scotia newspaper advertisement and two area physicians. From 40 patients (20 males, 20 females) who attended visit 1, 18 completed visits 1, 2 and the fl axseed oil intervention, and 14 completed visits 1, 2 and the saffl ower oil intervention. Eighteen males and 14 females completed this study. Th is study received approval from the Cape Breton University Human Ethics Review Committee and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all study participants.
Management protocol. Th e experimental design is outlined in Figure 1 . Subjects came fasted (12-14 h) for the fi rst visit, at which the time of the study was explained before they were consented. Th ree months later, patients came for the second visit. Aft er these two visits, the subjects continued with their normal daily activities without intervention. At the 2nd visit, the patients were randomized into ALA rich (~57.2 weight %) fl axseed oil (60 mg ALA/kg body weight/ day) or ALA poor (< 0.1 weight %) saffl ower oil in the form of 1 g gelatin capsules for three months until the 3rd visit (all patients consumed approximately 103 mg of oil/kg body weight/day). On all the visits, the age and sex of participants were noted, and body weight and height as well as body mass index (BMI) were determined. Diet, exercise, smoking, and medication records were kept by the patients throughout the study and collected at each visit.
Th e study design allowed no intervention for three month which allowed to establish the stability of fasting serum glucose (FSG), and insulin concentrations (FSI) (Barre et al. 2008) . Th e intervention during the following three months required random intervention with fl axseed oil or placebo (saffl ower oil). Accurate assessment of the impact of fl axseed oil on HOMA-IR and HOMA-%β required three-month period. Th e extent of changes, if any, in the control group compared to those in the treated group allowed a decision on whether the fl axseed oil dose had any impact on HOMA-IR and/or HOMA-%β. Blood was withdrawn into redtop vacutainers and allowed to clot for 45 min at room temperature before spinning at 1000xg for 15 min. Serum was removed by transfer pipet being careful not disturbed the packed cells.
Free fatty acid extraction. Serum FFAs were determined by fi rst taking 2.0 ml of serum (that had been frozen at -80 °C until analysis), standards (dissolved in n-heptane) or UHP water (for use as blank) and spiking each with 50 μl of 500 mM 17:0 (in n-heptane) as an internal standard. Th en 0.5 ml spiked serum standard, samples and blanks were extracted using 2.5 ml of isopropanol-n-heptane-phosphoric acid (2 M) (40:10:1 v/v), vortexed, sonicated, vortexed, and then 1 ml of n-heptane and 1.5 ml UHP water added. Th en the spiked blanks, standards, and samples were vortexed and sonicated followed by centrifugation at 1000×g 10 min at 4 °C. Th e top layer (1.5 ml), with isolated FFAs (Mehta et al. 1998 ) was removed and dried under nitrogen at 100 °C.
Visit 1 -patients consent and give a blood sample; patients instructed to keep records of diet (including alcohol), exercise, medication (type and dose of each drug) and smoking patterns. Values for all parameters (weight, height, plasma insulin, glucose, HOMA-IR, HOMA-% (mol % free fatty acids are determined for visit 1).
3 months, no intervention with fl axseed oil or saffl ower oil (patients otherwise carry on with normal life patterns) 3 months, intervention with fl axseed oil or saffl ower oil (patients randomly assigned to fl axseed oil or saffl ower oil but otherwise carry on with normal life patterns) Visit 2 -patients return and give a blood sample; records are collected. Values for all parameters indicated above are averaged for visits 1 and 2
Visit 3 -patients return and give a blood sample; records are collected. Values for all parameters indicated above are determined. HPLC separation of FFAs. Individual FFAs were then derivatised with phenacyl bromide using β-bromoacetophenone, triethylamine and acetic acid (Mehta et al. 1998) . Samples, standards and blanks were then dried down under nitrogen in a dry block at 100°C and reconstituted with 200 μl (166 μl of acetonitrile fi rst followed by 34 μl of water) of mobile phase (acetonitrile:water, 83:17 v/v). Samples, standards and blanks were then vortexed and centrifuged to remove any particulate matter, the supernatant removed and mixed with 600 μl of mobile phase. Fatty acid analysis was done by HPLC using a Waters Resolve C18 5 μm 3.9×300 mm column, a Waters 717 Plus autosampler, 600 pump and controller and a Waters 2487 UV/VIS detector. Th e injection volume was 100 μl of mobile phase containing the derivatised FAs with a mobile phase fl ow rate of 2 ml/min for 5 h with 242 nm detection. Peaks were identifi ed by comparison with retention time of certifi ed FA standards that had been derivatised with phenacyl bromide as above (Mehta et al. 1998) . Mol % FFAs were calculated.
Glucose, insulin, HOMA-IR and HOMA-%β. Glucose was measured by a C2 kit (Wako, Richmond, Virginia, USA) and serum insulin measured by human insulin ELISA kit (Linco, St. Charles, Missouri, USA) according to the manufacturer's directions. Th e glucose and insulin values have been published previously (Barre et al. 2008) .
HOMA-IR was calculated by multiplying FSG (mmol/l) by FSI (mU/L) and dividing the product by 22.5 while HOMA-%β is determined by the formula (20 × FSI)/(FSG -3.5) (Matthews et al. 1985) . In both formulae, glucose was measured in mmol/L and insulin in mU/L. Statistical analysis. Power was 0.80 to see a diff erence of 1 mmol of glucose/l using 12 subjects per group with p<0.05. Males and females were combined to give suffi cient statistical power. For a given parameter (FFAs, insulin, glucose, HOMA-IR and HOMA-%β) and person, visits 1 and 2 were averaged. A general linear model analysis (repeated measures) was performed with a signifi cance level of p<0.05. Pearson correlations were done between each of the averaged (for visits 1 and 2) baseline serum individual FFA mol % levels and averaged visit 1 and 2 values for each of each of HOMA-IR and HOMA-%β (Table 4) . Pearson correlations were done also between each of fl axseed oil and saffl ower oil-driven consumptiondriven individual FFA levels and each of HOMA-IR and HOMA-%β (visit 3) (Table 5 and Table 6 , respectively) (Roscoe 1975) .
Results
Composition of fl axseed and saffl ower oils is found in Table 1 . Th e single greatest level of FA in the fl axseed oil is ALA.
Oil and ALA consumption in g/day and mg/kg body weight/day for each of fl axseed oil, saffl ower oil, and ALA is found in Table 2 . Oil mass consumption was the same between fl axseed and saffl ower oil groups, though ALA consumption was much higher in the fl axseed oil consumers. Diet, smoking status, exercise and medications (type, dose) were consistent throughout the study. Table 3 reveals similarity of patient entry characteristics between those assigned to fl axseed and saffl ower oil groups (a two sample t-test showed no statistically signifi cant diff erence between the prevalues for each of BMI, plasma individual FFAs, glucose, insulin, HOMA-IR and HOMA-%β when fl axseed oil and saffl ower oil groups were compared. Table 4 shows the baseline correlations between each of the individual serum FFAs and each of HOMA-IR and HOMA-%β variables averaged for visits 1 and 2. Th e only signifi cant correlation pretreatment or placebo is the positive correlation of PA with HOMA-IR with trends (p<0.2) toward a posi- (Table 5) . Trends toward negative correlations between each of palmitelaidic acid (PEA, 16:1 n-7 trans), DHA and HOMA-IR were observed aft er fl axseed oil supplementation (Table 5) . Trends toward a positive correlation between myristoleic acid (MOA, 14:1 n-5 cis) and HOMA-%β and negative correlations between each of PEA, elaidic acid (EA, 18:1 n-9 trans), ALA and HOMA-%β occurred in fl axseed oil consumers (Table 5) .
Saffl ower oil consumers maintained the strong statistically signifi cant positive correlation between PA and HOMA-IR seen pre-supplementation while showing a positive trend with trans-vaccenic acid (TVA, 18:n-7 trans) and HOMA-IR with negative trend correlations between each of myristoleic acid (MOA, 14:1 n-5 cis), SA, AA, EPA and HOMA-IR (Table 6 ). Saffl ower oil consumers also showed a negative trend correlation between SA and HOMA-%β (Table 6) .
MA, PO, LA mol % levels dropped signifi cantly while ALA and EPA rose signifi cantly relative to baseline as the result of fl axseed oil supplementation (Table 7) . Saffl ower oil produced no changes in mol % FFA (Table 7) . Th ere was no statistically signifi cant diff erence between fl axseed oil and saffl ower oil treatment in going from pre-treatment (average of visits 1 and 2) to post treatment (visit 3) in terms of glucose, insulin, HOMA-IR and HOMA-%β (Table 8) .
Discussion
Baseline FFA composition was similar to a previous report on serum FFA composition in T2D (Yang et al 2004) . Individual FFAs pre-supplementation showed only a signifi cant positive correlation between PA and HOMA-IR with no signifi cant correlations between any of the fatty acids and HOMA-%β. Th e data of Stefan et al. (2010) have suggested a role for decreasing HOMA-IR via palmitoleate (PO, 16:1 n-7 cis) but this was not demonstrated by the data in the current study . In the review, De Caterina et al. (2007) have noted that both the serum levels of PA and PO appeared to be inversely related to insulin sensitivity. Th e PA fi nding has consistency with the current study's fi nding of a positive significant correlation between PA and HOMA-IR in the pre-supplementation and saffl ower supplementation interventions. Maris et al. (2011) suggested that oleate reduced β-cell function in vitro, a fi nding inconsistent with the current study. It is not clear from that paper that what type of oleate was used and whether that or any oleate might induce the same eff ect as OA in vivo (Tables 4-8 ). Other in vitro work has suggested a decrease in the insulin release by β-cell exposed to PA and OA (Maris et al. 2011 ). Fontes et al (2009 have shown the same response for PA (our work did not bear this out). Th e work of Oprescu et al. (2007) in rat islets showing a decreased insulin secretion resulting from the incubation with PA and OA is not consistent with the current study. In contrast, PA has been suggested to increase insulin release (Parker et al. 2003) in rat islets and in contrast, reduce preproinsulin synthesis (insulin gene activity) and perhaps by extension insulin and hence HOMA-%β (Kelpe et al. 2003 ) though this did not manifest in a change in correlations seen in the current study .
It seems that FFAs are more correlative preand post-supplementation with HOMA-IR than HOMA-%β though the signifi cance of this observation is not clear. Trends in correlations did not aff ect the outcomes to supplementation in terms of HOMA-IR and HOMA-%β. Muramatsu et al. (2010) have shown an association of increased dietary intake of ALA with reduced insulin resistance in healthy persons, although their association was not correlative but rather assessed in terms of lower absolute levels of HOMA-IR. Th is relationship is consistent with the statistically signifi cant negative correlation between ALA and HOMA-IR upon fl axseed oil supplementation seen in the current study. Wang et al. (2013) have found that feeding pure ALA decreased HOMA-IR in obese (not T2Ds) persons Table 7 Mol % blood serum free fatty acid composition (mol% levels) before and aft er fl axseed oil and saffl ower oil supplementation A general linear model analysis (repeated measures) was performed with a signifi cance level of p<0.05. FXO -fl axseed oil; SFO -saffl ower oil again consistent with the negative correlation seen in the current study. Nonetheless, the signifi cant negative correlation seen in our study between mol % serum free ALA levels and HOMA-IR, and the signifi cant increase in mol % levels of serum free ALA (Table 7) is consistent with a contribution to improved HOMA-IR or glycemic control in general (albeit overcome by indeterminate factors in our study and other works with fl axseed oil) (Barre et al. 2008; Foster et al. 2013; Taylor et al. 2010) . Consequently, one might suggest that it is the delivery (pure ALA versus ALA in oil format) that determines whether ALA reduces HOMA-IR. Th e lower ALA mol % levels seen in the study of Yi et al. (2007) in T2Ds are consistent with the negative correlation seen in the current study (Table 5) . Unlike the work of Asp et al. (2011) with saffl ower oil, the current study (Table 6 ) showed no change in the glycemic control despite saffl ower oil induced trends in some FA relationships with HOMA-IR and HOMA-%β not seen in the pre-treatment/placebo data (Table 4) .
Despite the signifi cant changes in blood serum mol % of some individual FFAs as the result of fl axseed oil or saffl ower administration (Table 7) , none of the FFAs correlated signifi cantly with HOMA-%β before or aft er the fl axseed or saffl ower oil consumption. It is consistent with the fi nding that fi sh oil rich in EPA and DHA did not infl uence HOMA-IR in T2Ds or the obese (Crochemore et al. 2012 ) (in fl axseed oil consumers, EPA and DHA can be derived from ALA). Various authors have observed either an increase or no impact on the blood plasma EPA levels and no impact on DHA levels as the result of ALA consumption in various oil formats (Ezaki et al. 1996; Hamazaki et al. 2006; Plourde and Cunnane 2007) . However, the current results refl ect a specifi c oil (fl axseed oil) and a specifi c pool (serum FFA) and so a comparison between papers using diff erent oils and diff erent blood plasma FA pools (e.g. phospholipid, total) is diffi cult.
Any individual statistically signifi cant correlation or trend toward such between a given FA level and each of HOMA-IR and HOMA-%β explained a relatively low contribution (r 2 value) to the variability of HOMA-IR and HOMA-%β by that FA. Indeed, there was no change in the HOMA-IR and HOMA-%β as the result of fl axseed oil compared to saffl ower oil administration (Table 8 ) consistent in terms of HOMA-IR fi ndings (Eyjolfson et al. 2004; Taylor et al. 2010) . Th ere appear to be no published studies on the impact of ALA or fl axseed oil on HOMA-%β.
Flaxseed oil consumption did not alter glucose, insulin, and HOMA-IR and/or HOMA-%β relative to placebo (saffl ower oil) (Table 8) . However, a larger study may demonstrate changes in one or more of these parameters for fl axseed oil versus saffl ower oil. While mol % individual FFAs and correlations between various serum individual FFA mol % levels and HOMA-IR and HOMA-%β can be manipulated signifi cantly by fl axseed oil, correlations arising from this supplementation, do not result in a shift in glucose, insulin, HOMA-IR and/or HOMA-%β despite changes in mol % FFAs induced by fl axseed oil . Th e absence of change in glucose, insulin, and HOMA-IR and/or HOMA-% β may be due to a fl axseed oil generated mix of negative and positive correlations cancelling one another out (Tables 4-6 ). It may be that feeding or perhaps infusing pure ALA will not only result in a negative correlation between HOMA-IR and ALA, but also in a statistically signifi cant HOMA-IR decrease with an, as yet indeterminate, impact on HOMA-%β. Flaxseed oil is mix of FAs each of which may have diff ering impacts on the correlations. However, this work shows that there are correlations and/or trends towards statistically signifi cant correlations between some serum individual free fatty acids and HOMA-IR and HOMA-%β. Th e fi ndings of the current study could not be infl uenced by unchanged patterns in diet, smoking, exercise or medications (dose/type) over the course of the study.
Th e signifi cance of this study is perhaps that the delivery platform (e.g. fl axseed oil versus pure ALA) of dietary FAs that infl uences whether a particular serum FFA can infl uence HOMA-IR and/or HOMA-%β and thus perhaps produce better clinical outcomes to the extent that diet may contribute to such. However, this remains to be further investigated. It also remains to investigate this study design using a large number of patients to address the limitation of the small number of patients in this study, HOMA-IR and/or HOMA-%β may be inaccurate or imprecise.
Th is is the fi rst publication, in which we are aware that diff erent relationships (correlations) and/or trends towards statistically signifi cant correlations between mol % levels of serum individual FFAs each of HOMA-IR and HOMA-%β in human T2D are shown and that these correlations can be manipulated by the administration of fl axseed oil and saffl ower oil.
In conclusion, the primary hypothesis that there would be diff erent relationships (correlations) between blood serum individual FFAs mol % levels and each of HOMA-IR and/or HOMA-%β in human
